Royal Bank of Canada reissued their hold rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a report issued on Wednesday. They currently have a $80.00 price objective on the biotechnology company’s stock.
Several other equities analysts have also recently commented on ENTA. TheStreet upgraded shares of Enanta Pharmaceuticals from a c+ rating to a b- rating in a report on Wednesday, December 13th. Zacks Investment Research cut shares of Enanta Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, January 30th. JPMorgan Chase cut shares of Enanta Pharmaceuticals from an overweight rating to a neutral rating in a report on Thursday, February 8th. BidaskClub cut shares of Enanta Pharmaceuticals from a strong-buy rating to a buy rating in a report on Saturday, February 10th. Finally, ValuEngine upgraded shares of Enanta Pharmaceuticals from a hold rating to a buy rating in a report on Thursday, March 1st. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and two have given a strong buy rating to the company’s stock. The company has an average rating of Buy and an average target price of $57.80.
Enanta Pharmaceuticals stock opened at $81.85 on Wednesday. Enanta Pharmaceuticals has a 12 month low of $29.23 and a 12 month high of $95.91. The firm has a market cap of $1,635.75, a PE ratio of 44.46 and a beta of 1.07.
Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.05 by $0.73. Enanta Pharmaceuticals had a net margin of 26.35% and a return on equity of 13.33%. The business had revenue of $38.11 million for the quarter, compared to analysts’ expectations of $27.26 million. sell-side analysts predict that Enanta Pharmaceuticals will post 0.86 earnings per share for the current year.
In related news, Treasurer Paul J. Mellett sold 9,000 shares of Enanta Pharmaceuticals stock in a transaction on Monday, March 19th. The shares were sold at an average price of $86.48, for a total value of $778,320.00. Following the completion of the sale, the treasurer now owns 96,458 shares of the company’s stock, valued at approximately $8,341,687.84. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 10.56% of the stock is currently owned by insiders.
Several hedge funds have recently added to or reduced their stakes in the stock. MetLife Investment Advisors LLC acquired a new stake in shares of Enanta Pharmaceuticals in the 4th quarter valued at $446,000. Macquarie Group Ltd. lifted its stake in shares of Enanta Pharmaceuticals by 350.0% in the 4th quarter. Macquarie Group Ltd. now owns 2,700 shares of the biotechnology company’s stock valued at $158,000 after purchasing an additional 2,100 shares during the last quarter. Millennium Management LLC acquired a new stake in shares of Enanta Pharmaceuticals in the 4th quarter valued at $12,959,000. Teachers Advisors LLC lifted its stake in shares of Enanta Pharmaceuticals by 3.0% in the 4th quarter. Teachers Advisors LLC now owns 28,668 shares of the biotechnology company’s stock valued at $1,682,000 after purchasing an additional 825 shares during the last quarter. Finally, HBK Investments L P acquired a new stake in shares of Enanta Pharmaceuticals in the 4th quarter valued at $221,000. 73.25% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Enanta Pharmaceuticals (ENTA) Receives “Hold” Rating from Royal Bank of Canada” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/07/enanta-pharmaceuticals-enta-receives-hold-rating-from-royal-bank-of-canada.html.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.